source
- Whoop appoints new chief medical officer, discusses health tech plans and CMS initiativeSTAT Health Tech’s latest newsletter features a brief interview with Whoop’s newly appointed chief medical officer. The CMO fielded three questions about the company’s direction, wearable data use…
- Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trialAtea Pharmaceuticals’ hepatitis C prospect has matched Gilead’s Epclusa in a phase 3 trial, keeping the biotech barreling toward a second readout for its shorter, simpler treatment regimen.